Sotac Pharma.
NSE: SOTAC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sotac Pharma.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company incorporated in 2015 that specialises in the manufacturing and sale of a diverse range of therapeutic products. Its portfolio spans various categories including anti-diabetic, cardiac, anti-infective, and dermatological treatments.
Business Model
The company generates revenue through the manufacturing and distribution of pharmaceutical formulations across multiple therapeutic segments. It operates as a manufacturer providing a broad spectrum of drugs, including antibiotics and chronic disease medications.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse therapeutic portfolio and the increasing demand for both chronic and acute pharmaceutical treatments in the Indian market.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and inspections by pharmaceutical regulatory authorities.
- Market Competition. The pharmaceutical sector in India is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can adversely impact the company's operational profitability.
- Product Liability. As a manufacturer of pharmaceutical products, the company is exposed to potential legal risks and reputational damage arising from product quality issues.
Start your research today
Unlock AI insights, financials, peers and live data on Sotac Pharma. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sotac Pharma.SOTAC | ₹100 Cr | — | — | — | 12.7% | — | — | -16.7% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Sotac Pharma.
NSE: SOTAC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Sotac Pharma.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company incorporated in 2015 that specialises in the manufacturing and sale of a diverse range of therapeutic products. Its portfolio spans various categories including anti-diabetic, cardiac, anti-infective, and dermatological treatments.
Business Model
The company generates revenue through the manufacturing and distribution of pharmaceutical formulations across multiple therapeutic segments. It operates as a manufacturer providing a broad spectrum of drugs, including antibiotics and chronic disease medications.
Growth Outlook
Growth is expected to be driven by the expansion of its diverse therapeutic portfolio and the increasing demand for both chronic and acute pharmaceutical treatments in the Indian market.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality control standards and inspections by pharmaceutical regulatory authorities.
- Market Competition. The pharmaceutical sector in India is highly fragmented and competitive, which may exert pressure on pricing and profit margins.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can adversely impact the company's operational profitability.
- Product Liability. As a manufacturer of pharmaceutical products, the company is exposed to potential legal risks and reputational damage arising from product quality issues.
Start your research today
Unlock AI insights, financials, peers and live data on Sotac Pharma. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026